Related Experiment Videos
Kidney diseases and chemokines.
Ulf Panzer1, Oliver M Steinmetz, Rolf A K Stahl
1Medizinische Klinik IV, Universtätsklinikum Hamburg Eppendorf, Hamburg, Germany.
Current Drug Targets
|February 4, 2006
Summary
Chemokines, signaling proteins that guide immune cells, are key in kidney inflammation. Blocking them shows therapeutic promise but requires precise timing and location to avoid worsening disease.
Area of Science:
- Nephrology
- Immunology
- Molecular Biology
Background:
- Inflammatory cells infiltrate the kidney, causing damage through direct cytotoxicity and soluble factors.
- Leukocyte migration to injury sites is crucial for renal damage or repair processes.
- Chemokines (chemoattractant cytokines) are primary regulators of leukocyte trafficking in health and disease.
Purpose of the Study:
- To review in vivo studies on chemokine and chemokine receptor neutralization in renal inflammatory diseases.
- To focus on the therapeutic potential of chemokine blockade in glomerulonephritis and renal transplantation.
Main Methods:
- Review of in vivo studies involving chemokine neutralization.
- Analysis of therapeutic effects of chemokine blockade in specific renal conditions.
Main Results:
- Chemokine blockade demonstrates potential for treating inflammatory renal diseases.
- Interference with chemokine pathways can exacerbate certain kidney diseases under specific conditions.
Conclusions:
- Chemokine blockade offers therapeutic promise for inflammatory kidney diseases.
- Effective chemokine inhibition strategies must be time- and compartment-specific for optimal renal benefit.